HemaCare Corp., a Sherman Oaks provider of blood-related services, has agreed to acquire MD Laboratories, a privately held firm that acquires and resells human blood plasma.
The transaction calls for HemaCare to exchange 280,000 shares of its common stock for the stock of MD Laboratories, although the number of shares involved is subject to adjustment. The deal would raise the number of outstanding HemaCare shares to 3.22 million.
HemaCare's stock currently is trading around $2 a share in over-the-counter trading, giving the acquisition an indicated value of about $560,000.
MD Laboratories, which has plasma centers in West Hollywood and Torrance, acquires and processes plasma from people who had infections or diseases that produce "unusual and valuable antibodies," the company said. MD Laboratories' customers further process the antibodies to create therapeutic products for other patients.